Virus injection takes on Hard-to-Treat cancers in early trial
NCT ID NCT06215846
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tests a single injection of a modified virus (BioTTT001) directly into tumors in 12 adults with advanced solid cancers that have not responded to standard treatments. The virus is designed to infect and kill cancer cells while also boosting the immune system. The main goals are to check safety, find the best dose, and see how the virus behaves in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BioTTT001 (a modified virus that targets cancer cells and delivers an immune-boosting protein)
What this could lead to
If it works, this could point toward a new way to treat advanced solid tumors by using a virus to attack cancer cells and stimulate the immune system.
What could go wrong
This is a very early Phase 1 trial with only 12 people, so it is mainly checking safety and dosing. The virus may not shrink tumors or could cause side effects like flu-like symptoms or inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of China Medical Univeristy
Shenyang, Liaoning, China